Rituximab, Apremilast, and Upadacitinib as Selected Biosimilar and Targeted Synthetic Disease-Modifying Antirheumatic Drugs with Diverse Mechanisms of Action: Their Current Use in Slowing Down the Progression of Disease

Ритуксимаб, апремиласт и упадацитиниб как избранные биосимилярные и таргетные синтетические базисные противоревматические препараты с различными механизмами действия: их современное применение для замедления прогрессирования заболевания
Tomasz Bączek, Piotr Kawczak, Igor Jarosław Feszak
2025-04-10

apremilastbiosimilar and targeted synthetic disease-modifying antirheumatic drugs (bsDMARDs and tsDMARDs)inflammatory arthritidesrituximabupadacitinib
Background/Objectives: Inflammatory arthritides includes a range of joint disorders, such as osteoarthritis and rheumatoid arthritis, as well as inflammatory conditions like gout and lupus. This review investigates the pathophysiology, therapeutic challenges, and evolving treatment landscape of arthritis, with a particular focus on the clinical roles of rituximab, apremilast, and upadacitinib. Methods: A comprehensive analysis was undertaken to evaluate the current clinical application, therapeutic efficacy, and safety profiles of selected biosimilar and targeted synthetic disease-modifying antirheumatic drugs (bsDMARDs and tsDMARDs). This overview placed particular emphasis on three key agents—rituximab, apremilast, and upadacitinib—each exemplifying distinct immunomodulatory mechanisms. By focusing on these agents, the analysis highlights the evolving landscape of targeted therapies in rheumatology and underscores the importance of personalized treatment selection based on the disease phenotype, prior therapeutic responses, and comorbid conditions. Results: Rituximab, apremilast, and upadacitinib each present valuable therapeutic options for patients who have shown inadequate response to conventional disease-modifying antirheumatic drugs (DMARDs) or nonsteroidal anti-inflammatory drugs (NSAIDs). Conclusions: Despite the complexity and heterogeneity of arthritis, agents like rituximab, apremilast, and upadacitinib have expanded the therapeutic possibilities in treating this disease and improved its management. Continued research is essential to optimize patient-specific treatment strategies and explore novel molecular targets.
1
Continued research is necessary to optimize patient-specific strategies and identify novel molecular targets for arthritis treatment.
2
Rituximab, apremilast, and upadacitinib exemplify distinct immunomodulatory mechanisms among bsDMARDs and tsDMARDs for inflammatory arthritides.
3
The review emphasizes personalized treatment selection based on disease phenotype, prior therapeutic responses, and comorbid conditions.
4
These three agents are valuable therapeutic options for patients with inadequate response to conventional DMARDs or NSAIDs.
5
Use of rituximab, apremilast, and upadacitinib has expanded therapeutic possibilities and improved management of heterogeneous arthritis.

Rituximab, apremilast, and upadacitinib as selected biosimilar and targeted synthetic disease-modifying antirheumatic drugs used in inflammatory arthritides

Their current clinical use, therapeutic efficacy, and safety profiles in slowing disease progression and managing inflammatory arthritides, with emphasis on distinct immunomodulatory mechanisms and personalized treatment selection

Publication Details
Publication Date
2025-04-10
Journal
Publisher
ISSN
Cited by
3
Access Type
Author Information
Authors
Tomasz Bączek
Piotr Kawczak
Igor Jarosław Feszak
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%